Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Financial report summary
?Competition
Antares Pharma • ANI Pharmaceuticals • Amphastar Pharmaceuticals • Vanda Pharmaceuticals • Ocular Therapeutix • Coherus Biosciences • Perrigo • ARS Pharmaceuticals • Morphic Holding • Amneal Pharmaceuticals Inc - Ordinary SharesRisks
- We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.
- Increasing scrutiny and evolving expectations from customers, regulators, governments, investors, lenders, employees, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.
- There can be no guarantee that we will continue to pay dividends or repurchase shares under our stock buyback program.
- If the intercompany terms of cross border arrangements that we have among our subsidiaries are determined to be inappropriate or ineffective, our tax liability may increase.
- We may not be able to maintain competitive financial flexibility and our corporate tax rate which could adversely affect us and our shareholders.
- Unanticipated changes in our tax provisions or exposure to additional income tax liabilities and changes in income tax laws and tax rulings may have a significant adverse impact on our effective tax rate and income tax expense.
- Currency fluctuations and changes in exchange rates have impacted and could continue to adversely affect our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
- There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.
- We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis.
- Viatris has suffered and in the future could suffer additional losses due to impairment charges.
- Viatris may be adversely affected by disruptions in the credit markets, including disruptions that reduce customers’ access to credit and increase the costs to customers of obtaining credit.
- Viatris has certain material obligations relating to defined benefit pension and termination benefit programs.
- The market price of our common stock has been and may continue to be volatile, and the value of your investment could materially decline.
- The expansion of social media platforms presents new risks and challenges.
- Provisions in the Viatris Charter and Viatris Bylaws and of applicable law may prevent or delay an acquisition of Viatris, which could decrease the trading price of Viatris common stock.
- The exclusive forum provisions in the Viatris Charter could discourage lawsuits against Viatris and its directors and officers.
Management Discussion
- (1)Currency impact is shown as unfavorable (favorable).
- (2)The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2023 constant currency net sales or revenues to the corresponding amount in the prior year.
- (3)For the year ended December 31, 2023, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately $26.1 million, $1.1 million, and $11.3 million, respectively.